Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Summary of the history of clinical manifestation of the SLE patients in cohort 3

From: The plasma biomarker soluble SIGLEC-1 is associated with the type I interferon transcriptional signature, ethnic background and renal disease in systemic lupus erythematosus

Phenotype EUR Non-EUR
N Affected patients, n (%) N Affected patients, n (%) ORa (95% CI) P valueb
Renal 320 75 (24.4%) 243 81 (33.3%) 1.60 (1.11–2.32) 0.01
Neurological 330 36 (10.9%) 244 42 (17.2%) 1.67 (1.05–2.74) 0.03
Haematological 366 185 (50.5%) 268 106 (39.6%) 0.65 (0.47–0.89) 0.007
dsDNA positivity 370 143 (38.6%) 270 83 (30.7%) 0.70 (0.51–0.98) 0.04
Admission ratec 351 140 (39.9%) 196 86 (43.9) 1.20 (0.84–1.71) 0.31
Biologics ever neededd 332 23 (6.9%) 239 12 (5.0%) 0.70 (0.34–1.43) 0.33
  1. Summary of available clinical history for the 656 study participants from cohort 3 since their disease diagnosis and up to the time of their visit. Data were stratified by study cohort
  2. CI confidence interval, EUR patients of European ancestry, non-EUR patients of non-European ancestry, SLE systemic lupus erythematosus
  3. aOdds ratio (OR) in non-European patients
  4. bP values calculated using Pearson’s chi-squared test
  5. cAdmission defined as any patient requiring hospital admission specifically for SLE in the 5 years prior to and including the date of their clinic visit at which the blood sample was taken
  6. dPatients treated with biologic drugs at any time since their disease diagnosis